Edition:
United States

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

16.40USD
28 Apr 2017
Change (% chg)

$-0.60 (-3.53%)
Prev Close
$17.00
Open
$15.95
Day's High
$16.60
Day's Low
$15.00
Volume
363,168
Avg. Vol
158,304
52-wk High
$17.20
52-wk Low
$7.19

Latest Key Developments (Source: Significant Developments)

Cytokinetics Q1 loss per share $0.62
Thursday, 27 Apr 2017 04:00pm EDT 

April 27 (Reuters) - Cytokinetics Inc ::Cytokinetics, inc. Reports first quarter 2017 financial results.Q1 revenue $4.2 million versus $8.4 million.Q1 loss per share $0.62.Q1 earnings per share view $-0.61, revenue view $20.8 million -- Thomson Reuters I/B/E/S.  Full Article

Cytokinetics announces start of second cohort in Phase 2 clinical trial of CK-2127107
Wednesday, 29 Mar 2017 07:30am EDT 

Cytokinetics Inc :Cytokinetics announces start of second cohort in phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy.  Full Article

Cytokinetics and Origent Data Sciences report advancement of research collaboration
Thursday, 23 Mar 2017 07:30am EDT 

Cytokinetics Inc : Cytokinetics - co, Origent Data Sciences announced advancement of their research collaboration . Collaboration to prospectively validate origent's computer model to predict course of als disease progression .Cytokinetics - collaboration to predict course of als disease progression using data from vitality-als, cos' ongoing phase 3 clinical trial of tirasemtiv.  Full Article

Cytokinetics Q4 EPS $0.16
Thursday, 16 Feb 2017 04:00pm EST 

Cytokinetics Inc : Cytokinetics, inc. Reports fourth quarter 2016 financial results . Q4 revenue $33.1 million versus $9.8 million . Q4 revenue view $16.3 million -- Thomson Reuters I/B/E/S . Q4 earnings per share $0.16 . Q4 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Cytokinetics inc sees anticipates 2017 cash revenue will be in range of $21 to $23 million . Cytokinetics inc -expect to continue to enroll patients who complete vitality-als into vigor-als, an open-label extension trial throughout 2017 . Cytokinetics inc -expect to begin a phase 2 clinical trial of ck-2127107 in patients with als in mid-2017 . Cytokinetics inc -expect astellas to begin a phase 1b clinical trial of ck-2127107 in elderly patients with limited mobility in 1h 2017 . Cytokinetics inc -expect data from a phase 2 clinical trial of omecamtiv mecarbil in japanese patients with chronic heart failure in q3 2017 .Cytokinetics inc sees 2017 cash research and development expenses will be in range of $108 to $112 million, and cash g&a expenses will be in range of $30 to $32 million.  Full Article

Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil
Thursday, 2 Feb 2017 07:30am EST 

Cytokinetics Inc : Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil . Cytokinetics Inc - to sell to royalty pharma a portion of potential royalty due to Cytokinetics from Amgen on worldwide sales of Omecamtiv Mecarbil . Cytokinetics says sold to Royalty Pharma a 4.5 percent royalty on potential worldwide sales of Omecamtiv Mecarbil for $90 million in an upfront cash payment . Says Royalty Pharma has agreed to purchase $10 million of Cytokinetics' common stock . Has also agreed to exercise its option to co-invest with amgen in phase 3 development program of Omecamtiv Mecarbil . Cytokinetics - to exercise its co-investing option in exchange for increased royalties from amgen on worldwide sales of Omecamtiv Mecarbil outside Japan . Cytokinetics - agreed with Royalty Pharma to exercise option to co-invest $40 million in phase 3 development program of Omecamtiv Mecarbil under deal with Amgen .Cytokinetics - following transaction with Royalty Pharma, Cytokinetics retains right to receive more than $600 million in potential milestone payments.  Full Article

Cytokinetics starts phase 3 clinical trial of omecamtiv mecarbil
Thursday, 1 Dec 2016 07:30am EST 

Cytokinetics Inc: Cytokinetics announces start of galactic-hf, a phase 3 clinical trial of omecamtiv mecarbil . Coincident with start of trial, Amgen will make a $26.7 million milestone payment to CytoKinetics .Cytokinetics - galactic-hf will be conducted under a special protocol assessment (spa) with U.S. FDA.  Full Article

Cytokinetics Q3 earnings per share $0.80
Thursday, 27 Oct 2016 04:00pm EDT 

Cytokinetics Inc : Cytokinetics Inc reports third quarter 2016 financial results . Q3 revenue $59 million versus $7.9 million . Q3 revenue view $8.4 million -- Thomson Reuters I/B/E/S . Q3 earnings per share $0.80 . Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S .Anticipates 2016 cash revenue will be in range of $84 to $87 million.  Full Article

Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3
Thursday, 1 Sep 2016 08:30am EDT 

Cytokinetics Inc : Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3 clinical development . Phase 3 outcomes trial will be conducted by Amgen in collaboration with Cytokinetics .Company and Amgen are also planning a potential exercise performance/cardiac function clinical trial to be conducted by Cytokinetics.  Full Article

Cytokinetics Inc reports q2 2016 financial results
Thursday, 28 Jul 2016 04:00pm EDT 

Cytokinetics Inc : Will not update financial guidance until Q3 earnings due to recent expansion of collaboration with Astellas . Cytokinetics, Inc. reports second quarter 2016 financial results . Q2 loss per share $0.29 . Q2 revenue $5.8 million versus $6.5 million . Q2 revenue view $10.2 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S . Expect to make a decision regarding advancement of omecamtiv mecarbil to phase 3 in Q3 of 2016 ."We will not update our financial guidance until our Q3 earnings due to recent expansion of our collaboration with Astellas".  Full Article

Cytokinetics, Astellas announce option right for Tirasemtiv
Wednesday, 27 Jul 2016 07:30am EDT 

Cytokinetics Inc : Cytokinetics and Astellas announce option right for Tirasemtiv and expansion of global collaboration for CK-2127107 in ALS . Option has potential for more than $100 million in payments associated with exercise of option . To receive $65 million in upfront payments, $30 million in additional sponsored research and development .Companies to extend joint research focused on discovery of skeletal muscle activators through 2017.  Full Article

More From Around the Web

BRIEF-Cytokinetics Q1 loss per share $0.62

* Cytokinetics, inc. Reports first quarter 2017 financial results